Willner & Heller LLC reduced its position in Axon Enterprise, Inc (NASDAQ:AXON – Free Report) by 63.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 478 shares of the biotechnology company’s stock after selling 834 shares during the period. Willner & Heller LLC’s holdings in Axon Enterprise were worth $268,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently made changes to their positions in AXON. Vanguard Group Inc. raised its position in Axon Enterprise by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock valued at $5,319,928,000 after acquiring an additional 53,060 shares in the last quarter. Geode Capital Management LLC grew its position in Axon Enterprise by 1.6% in the fourth quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock worth $1,265,657,000 after acquiring an additional 35,544 shares in the last quarter. Baillie Gifford & Co. increased its stake in shares of Axon Enterprise by 1,198.7% during the 4th quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock worth $932,869,000 after purchasing an additional 1,516,099 shares during the last quarter. Sands Capital Management LLC increased its stake in shares of Axon Enterprise by 11.6% during the 4th quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock worth $914,047,000 after purchasing an additional 167,095 shares during the last quarter. Finally, Wellington Management Group LLP raised its holdings in shares of Axon Enterprise by 326.9% during the 4th quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock valued at $874,463,000 after purchasing an additional 1,179,038 shares in the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.
Axon Enterprise News Roundup
Here are the key news stories impacting Axon Enterprise this week:
- Positive Sentiment: Revenue increased 35.3% year over year to $904.4 million, exceeding analysts’ expectations of approximately $876 million. Annual recurring revenue rose 39% to $1.6 billion, while net revenue retention reached 126%. Axon Q2 2026 revenue release
- Positive Sentiment: Growth was particularly strong in newer businesses: AI Era revenue nearly quadrupled from the prior year, Platform Solutions revenue increased 123% to $150 million, and Dedrone counter-drone revenue surpassed $100 million. Management also raised its full-year revenue-growth outlook to 32%-34% while maintaining its 25.5% adjusted EBITDA margin target. Axon AI and drone growth report
- Neutral Sentiment: Non-GAAP earnings were $1.88 per share, roughly in line with or slightly above different analyst estimates, but down from $2.12 a year earlier. Reported net income was $29 million, compared with $155 million in non-GAAP net income, highlighting the impact of adjustments. Axon Q2 earnings metrics
- Negative Sentiment: Quarterly gross margin declined as professional services represented a larger share of sales and the company invested to scale newer products. Higher inventory also raised concerns about working-capital efficiency. Reuters report on Axon margins
- Negative Sentiment: The reaction reflects elevated expectations for AXON, which trades at a very high valuation. Investors may be concerned that rapid AI and hardware expansion will take time to translate into sustained earnings growth, particularly as the company’s net margin remains modest. Axon margin and inventory report
Analyst Ratings Changes
Check Out Our Latest Analysis on AXON
Axon Enterprise Price Performance
NASDAQ AXON opened at $609.49 on Thursday. The stock has a 50-day simple moving average of $509.69 and a 200 day simple moving average of $474.71. Axon Enterprise, Inc has a twelve month low of $339.01 and a twelve month high of $885.00. The stock has a market capitalization of $49.12 billion, a PE ratio of 244.78, a P/E/G ratio of 12.39 and a beta of 1.39. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27.
Axon Enterprise (NASDAQ:AXON – Get Free Report) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $1.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.84 by $0.04. The firm had revenue of $904.39 million for the quarter, compared to analyst estimates of $876.42 million. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The company’s revenue was up 35.3% on a year-over-year basis. During the same quarter last year, the firm posted $2.12 EPS. Research analysts anticipate that Axon Enterprise, Inc will post 1.63 EPS for the current year.
Insider Buying and Selling
In related news, insider Elizabeth Reid Coughlin sold 1,554 shares of the company’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $485.00, for a total transaction of $753,690.00. Following the completion of the transaction, the insider directly owned 34,024 shares in the company, valued at $16,501,640. This represents a 4.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Caitlin Elizabeth Kalinowski sold 564 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $478.97, for a total transaction of $270,139.08. Following the transaction, the director owned 3,632 shares of the company’s stock, valued at approximately $1,739,619.04. The trade was a 13.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 58,989 shares of company stock valued at $30,527,983 in the last ninety days. Company insiders own 4.20% of the company’s stock.
About Axon Enterprise
Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.
Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.
Featured Stories
- Five stocks we like better than Axon Enterprise
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc (NASDAQ:AXON – Free Report).
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.
